Symbiotec Pharmalab IPO Day 3 Subscription Status: Issue Subscribed 5.60x as NII Demand Surges

Mumbai, August 26: The Symbiotec Pharmalab IPO picked up considerable steam on the third day of bidding. The ₹1,757 crore issue was subscribed 5.60 times by 5:09 PM on August 26, according to the latest subscription data.

The issue received bids for 6,97,96,905 shares, against 1,24,60,533 shares offered to investors. At the upper end of the ₹938-₹988 price band, the total value of bids stood at around ₹6,895.93 crore. The number of applications had reached 19,72,612.

The biggest push came from Non-Institutional Investors (NII). Their portion was subscribed 12.83 times, with the sNII category leading at 14.70x and the bNII portion at 11.90x.

Retail investors were active too. Their portion was subscribed 5.34 times, while the employee reservation saw 6.21x subscription.

The one category still trailing is QIBs. The QIB portion, after excluding shares already allotted to anchor investors, was subscribed 0.62 times as of the latest update.

Symbiotec Pharmalab IPO Subscription Status Day 3

As of 5:09 PM on August 26, the category-wise subscription stood at:

• Overall: 5.60x
• QIB (Ex-Anchor): 0.62x
• NII: 12.83x
• bNII (> ₹10 lakh): 11.90x
• sNII (< ₹10 lakh): 14.70x
• Retail: 5.34x
• Employees: 6.21x
• Total Applications: 19,72,612

The numbers make the investor mix pretty clear. NII demand is doing most of the heavy lifting, while retail participation has also moved well beyond the amount of shares reserved for the category.

QIB participation, however, is yet to reach the 1x mark. That makes the final day of bidding worth watching, particularly to see whether institutional demand catches up.

Day-Wise Subscription Trend

Symbiotec Pharmalab IPO had a fairly modest start, with the issue subscribed 0.85x on Day 1. Demand improved to 1.95x on Day 2 before jumping to 5.60x on Day 3.

The jump in NII participation stands out. Their subscription moved from 3.16x on Day 2 to 12.83x on Day 3.

Retail demand also more than doubled during the same period, moving from 2.22x to 5.34x. QIB subscription improved from 0.57x to 0.62x, although it remains below full subscription.

Symbiotec Pharmalab IPO Details

Symbiotec Pharmalab is a ₹1,757 crore bookbuilding IPO made up of a fresh issue and an offer for sale.

• Total Issue Size: ₹1,757 crore

• Fresh Issue: ₹150 crore

• Offer for Sale: ₹1,607 crore

• Price Band: ₹938 to ₹988 per share

• Lot Size: 15 shares

• Minimum Retail Investment: ₹14,820

• Face Value: ₹2 per share

• Listing: BSE and NSE

• Issue Type: Bookbuilding IPO

• Employee Discount: ₹90 per share

At the upper price of ₹988, one retail lot of 15 shares costs ₹14,820.

The company has also kept a reservation of up to 33,408 shares for employees, with an employee discount of ₹90 on the issue price.

IPO Reservation

The net issue has been divided among QIBs, NIIs and retail investors:

• QIB: 88,76,517 shares — 50%

• NII: 26,62,955 shares — 15%

• Retail: 62,13,562 shares — 35%

• Employees: 33,408 shares

Before the public issue opened, Symbiotec Pharmalab raised ₹526.20 crore from anchor investors through 53,25,909 shares.

Symbiote Pharmalab IPO Allotment and Listing Date

The IPO is scheduled to close on August 27, 2026. Based on the tentative timetable, investors can expect the following:

• IPO Close: August 27, 2026
• Allotment: August 28, 2026
• Refunds: August 31, 2026
• Shares Credited to Demat: August 31, 2026
• Tentative Listing: September 1, 2026

These dates are tentative and can change during the allotment and listing process.

About Symbiotec Pharmalab Ltd.

Symbiotec Pharmalab Ltd. was incorporated in 2002 and operates in the pharmaceutical and biotechnology sector. The company develops and manufactures active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.

The company has built its operations around a backward-integrated manufacturing model and serves customers in both domestic and overseas markets.

Its regulatory approvals and certifications include US FDA and EU-GMP, along with approvals from other international regulatory authorities. The company has also been operating in the pharmaceutical ingredients space for several years, with its business evolving from its earlier focus on steroidal hormone APIs.

Conclusion

The Symbiotec Pharmalab IPO was subscribed 5.60 times by 5:09 PM on August 26, with demand accelerating sharply during the third day of bidding.

NII investors led the show at 12.83x, while retail investors subscribed 5.34x and employees 6.21x. QIB demand was comparatively slower at 0.62x, excluding the anchor portion.

With the issue closing on August 27, the final bidding day could still change the overall subscription figure and investor-category mix. For investors considering the IPO, the subscription numbers are useful for gauging demand, but they should not be treated as a standalone investment signal. The company’s fundamentals, valuation and the risks outlined in the offer documents also deserve a close look.

Source:

• https://www.nseindia.com/market-data/issue-information?symbol=SYMBIOTEC&series=EQ&type=Active